Ferroptosis-related ACSL3 and ACTC1 predict metastasis free survival for prostate cancer patients unfergoing radical radiotherapy

BACKGROUND To develop a ferroptosis-related gene prognostic index (FGPI) to predict biochemical recurrence and metastasis for prostate cancer (PCa) patients undergoing radical radiotherapy. METHODS All analyses were conducted with R version 3.6.3 and its suitable packages. RESULTS ACSL3 and ACTC1 were used to establish the FGPI score. Patients in high-risk group had higher risk of BCR (HR: 2.52, 95%CI: 1.49–4.26; p = 0.001) and metastasis (HR: 4.89, 95%CI: 2.12–11.29; p = 0.001) than those in low-risk group, and these results were consistent with external validation of TCGA database (BCR: HR:1.74, 95%CI: 1.04–2.91; MFS: HR: 2.23, 95%CI: 1.44–3.44). Moreover, the diagnostic accuracy of FGPI was also confirmed. Patients in higher expression of lncRNA PART1 had significantly lower risk of metastasis compared to their counterpart (HR: 0.27, 95%CI: 0.10–0.72). Gene set enrichment analysis showed that high-risk patients were negatively associated with integrin signaling pathway, laminin interactions, and fatty acid biosynthesis. PHA-793887 might be sensitive to ACSL3 and ACTC1, and the possible cell lines used to investigate were PC3 and DU145. CONCLUSIONS We found that FGPI based on ACSL3 and ACTC1 might be used to predict BCR and metastasis probability for PCa patients.